Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a Healthcare company (Biotechnology) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Sarepta Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.77, Sarepta Therapeutics, Inc. trades at 164.0x trailing earnings, 0.8x sales and 1.0x book value, with an EV/EBITDA of 13.9. Over the last twelve months it generated about $2.0B of revenue and $10M of net income. It runs a gross margin of 56.2%, an operating margin of -2.5% and a net margin of 0.8%. It shows return on equity of 1.0%, return on invested capital of -0.7% and a free cash flow yield of -2.0%. On the balance sheet: a debt-to-equity ratio of 0.69 and a current ratio of 3.46. Over the past 52 weeks the share price ranged from $14.58 to $24.68, with a beta of 0.20.
Sarepta Therapeutics, Inc. does not currently pay a dividend.
55 Wall Street analyst ratings cover the stock: 31 Buy, 18 Hold and 6 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.